低分子肝素钙和小剂量肝素在高危出血倾向患者血液透析中的疗效比较

目的对比观察低分子肝素钙和小剂量肝素在高危出血倾向患者血液透析中的治疗效果。方法从我院具有高危出血倾向维持血液透析患者中抽取60例，随机分为观察组与对照组，观察组患者使用低分子肝素钙治疗，对照组患者使用小剂量肝素治疗。对比观察两组患者治疗前后凝血情况和血常规检查情况。结果观察组患者治疗后穿刺点所需压迫时间、潜血转阴时间明显短于对照组，差异有统计学意义（P〈0．05l两组患者透析后血小板计数均有下降，凝血活酶时间（APlTr）及凝血酶时间（TT）明显延长（P〈0．05），且观察组患者APTT和TT比对照组明显缩短（P〈0．05）。结论在对具有高危出血倾向的血液透析患者临床治疗中，低分子肝素钙比小剂量肝素更具有优势，且安全性更为理想。

The efficacy of low molecular weight heparin versus that of low-dose heparin for patients with high-risk bleeding on hemodialysis

Objective To compare the efficacy of low molecular weight heparin with that of low-dose heparin for patients with high-risk bleeding on hemodialysis, blelhod8 60 patients undergoing maintenance hemodialysis who had a high risk of bleeding were selected and then were randomly divided into two groups. The study group received low molecular weight heparin; and the control group received low-dose heparin, Results The required compression time for puncture point and time for occult blood clearance was significantly shorter in the study group than in the control group, with a significant statistical difference （P〈0.05）. After hem0dialysis, platelet count was decreased while APTF and TT were significantly prolonged （P〈0.05）, and APTT and TT were markedly shortened in the study group than in the control group （P〈0.05）. Conclusions In the treatment of patients wih high-risk bleeding on hemodialysis, low molecular weight heparin has more advantages than low-dose heparin and is saferl.